Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2015 09:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals Announces Expansion of Management Team

SOUTH SAN FRANCISCO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that Jeff Jonker has been named President and...
March 02, 2015 07:30 ET | Source: Advaxis

Advaxis to Present at the Cowen and Company 35th Annual Health Care Conference

PRINCETON, N.J., March 2, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor,...
February 26, 2015 07:30 ET | Source: Advaxis

Advaxis to Present at International Anal Neoplasia Society Scientific Meeting 2015

Phase 1/2 Clinical Study Data on ADXS-HPV in HPV-Associated Anal Cancer Selected for Oral Presentation Keynote Speech to be Delivered by Samir N. Khleif, M.D., Member of Advaxis's Board of...
February 18, 2015 12:15 ET | Source: Advaxis

Advaxis Completes $23 Million Financing

PRINCETON, N.J., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that it has executed definitive...
February 18, 2015 05:04 ET | Source: Research and Markets

Global Vaccine Market 2014-2019: Technology Analysis - Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell & Inactivated

Dublin, Feb. 18, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/krz49b/vaccine_market_by) has announced the addition of the "Vaccine Market...
February 13, 2015 10:30 ET | Source: Advaxis

Advaxis Appoints Mayo Pujols Vice President, Manufacturing

PRINCETON, N.J., Feb. 13, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Mayo...
February 11, 2015 07:30 ET | Source: Advaxis

Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer

PRINCETON, N.J., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial...
February 05, 2015 07:30 ET | Source: G1 Therapeutics

G1 Therapeutics Raises $33 Million in Series B Financing

Proceeds to accelerate clinical development of lead CDK4/6 inhibitor for antineoplastic and chemoprotection indications Fred Eshelman and Peter Kolchinsky join board of...
February 02, 2015 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals to Present at Upcoming Investor Conferences

PLYMOUTH MEETING, Pa., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that President and CEO, Dr. J. Joseph Kim, will present a corporate overview at the...
January 28, 2015 07:30 ET | Source: Advaxis

Gynecologic Oncology Group (GOG) Phase 2 Study of Advaxis's Lm-LLO Immunotherapy, ADXS-HPV, for the Treatment of Persistent or Recurrent Cervical Cancer Achieves Safety and Efficacy Criteria

PRINCETON, N.J., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced an update related to the Phase 2...